A Dose of COVID-19 Vaccine Offers Solid Protection Against Severe Disease.
Research has proven that a single dose COVID-19 vaccine has been shown to deliver solid protection against severe disease and death. The vaccine, made by Johnson & Johnson (J&J), had 85% efficacy against COVID-19–related fatalities or severe symptoms in all age groups, regardless of a person’s other underlying medical conditions, the company announced today. Its efficacy against mild cases of the disease was lower, and dropped to 57% in South Africa, where a viral variant that can dodge immune responses now dominates. The vaccine revealed equally effective regardless of the viral strain, a result many vaccine experts hailed.
Should in Case you can prevent severe disease in a high you of individuals, that will eradicate so much of the stress in human suffering and death in this epidemic,” said Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, at a telephone press conference this morning. Nahid Bhadelia, an infectious disease physician who is medical director of the special pathogens unit at Boston Medical Center, added that a single-dose vaccine could be a benefit for people living in rural places and those who might have difficulty getting a second dose.
Test tubes are also prepped to receive a dose of the Johnson & Johnson COVID-19 vaccine, which the company says has strong prevention against the disease. The 85% efficacy against severe disease everywhere in different country trial increase to 100% protection when only considering deaths or COVID-19 cases that required hospitalization. The Johnson & Johnson results come less than 24 hours after another COVID-19 vaccine success reported by the small biotech Novavax.
The Johnson & Johnson vaccine, which was produced by its Janssen Pharmaceuticals division, contains a gene for the SARS-CoV-2 spike protein stitched into adenovirus 26 (Ad26), which normally causes common colds but has been disabled so that it cannot occur again. The interim result announced today, described only in a press release so far, found 468 cases of symptomatic COVID-19 among the participants—far more than any other COVID-19 vaccine efficiency trial to date, which produce more confidence that the results are robust. Some protection was seen as early as 14 days after the dose, and by day 28, the overall efficiency against COVID-19 cases with any noticeable symptoms was 72% among trial participants in the United States, 66% in Latin America, and 57% in South Africa.
Johnson & Johnson (J&J) single-dose option could boost the world’s fight against SARS-CoV-2. All of the other COVID-19 vaccines with proven protection to date require a second dose weeks later. A single dose vastly simplifies administering vaccines, and the Johnson & Johnson product can also be transported under normal refrigeration, not the subzero temperatures required for the messenger RNA (mRNA) vaccines. Brazil has the same variant to the one in South Africa that appears to have weakened the J&J vaccine’s overall efficacy.